close_bt
img
close_bt
THE ENTEROBIOME

WHO WE ARE

COMPETITIVITY

COMPETITIVITY

ico
img
  • ico1

    DIVERSITY

    Strain library of dozens of anaerobic bacterial species is already constructed (e.g. A. muciniphila and F. prausnitzii) and being expanded.
  • ico2

    PRODUCTIVITY

    Patented cultivation and optimization method for hardly cultivable gut bacterial species
    Achievement of mass production technology
  • ico3

    NOVELTY

    Novel and patented application of microbiome
    MODE OF ACTION identified for selected strains to act in disease treatment
  • ico4

    TECHNOLOGY

    Efficacy evaluation technology
    Establishment of efficient methods to select highly efficacious strains
  • ico5

    ANALYSIS

    Analytical skills for microbiome development
    Mechanism study based on metagenomic analysis
    Mechanism study based on metabolite analysis

We have secured the foundation for competitiveness through the completion of the world-scale library construction of A. muciniphila and F. prausnitzii

A. muciniphila (AM)
img1 img2 img3
F. prausnitzii (FP)
img4 img5 img6
*Genomic analysis and toxicity profiling for the verification of the functionality and safety

Secured technology for screening efficacious microbiome strain

  • img7
    01
    Fecal sample
  • img8
    02
    Next generation Sequencing
  • img9
    03
    Gut microbiota analysis
  • img10
    04
    A. muciniphila
  • img11
    05
    Securing microbial
    and genetic resources
    beneficial for human use
  • img12
    06
    Strain library, safety
    evaluation, animal model
    study, product development
  • img13
    07
    Mass production via
    optimization of cultivation
In vitro

BMDC, PBMC
3T3L-1 : ELISA, PCR

img14
img15
img16
Control
img17
BAA-835
img18
EB-AMDK19
EX vivo

Splenocyte, organoid

img19
img20
Laboratory rat
img21
Spleen, ELISA
img22
Control
img23
EB-AMDK19
In vivo

HFD-induced
obesity model

img24
img25

Oral administration
of bacteria

Efficacy evaluation
in animal models